NasdaqGM:APEN

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices. More Details


Snowflake Analysis

Adequate balance sheet with limited growth.


Similar Companies

Share Price & News

How has Apollo Endosurgery's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: APEN is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: APEN's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.


Market Performance


7 Day Return

16.1%

APEN

-1.7%

US Medical Equipment

1.8%

US Market


1 Year Return

-0.4%

APEN

18.1%

US Medical Equipment

20.4%

US Market

Return vs Industry: APEN underperformed the US Medical Equipment industry which returned 18.4% over the past year.

Return vs Market: APEN underperformed the US Market which returned 19% over the past year.


Shareholder returns

APENIndustryMarket
7 Day16.1%-1.7%1.8%
30 Day62.4%-0.6%6.0%
90 Day91.2%5.4%6.8%
1 Year-0.4%-0.4%19.1%18.1%23.2%20.4%
3 Year-48.0%-48.0%68.5%64.2%47.4%37.6%
5 Yearn/a135.9%117.8%91.9%70.8%

Long-Term Price Volatility Vs. Market

How volatile is Apollo Endosurgery's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Apollo Endosurgery undervalued compared to its fair value and its price relative to the market?

6.39x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: APEN ($2.81) is trading above our estimate of fair value ($2.79)

Significantly Below Fair Value: APEN is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: APEN is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: APEN is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate APEN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: APEN is overvalued based on its PB Ratio (6.4x) compared to the US Medical Equipment industry average (4.5x).


Next Steps

Future Growth

How is Apollo Endosurgery forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

21.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: APEN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: APEN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: APEN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: APEN's revenue (34.2% per year) is forecast to grow faster than the US market (10.2% per year).

High Growth Revenue: APEN's revenue (34.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if APEN's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Apollo Endosurgery performed over the past 5 years?

2.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: APEN is currently unprofitable.

Growing Profit Margin: APEN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: APEN is unprofitable, but has reduced losses over the past 5 years at a rate of 2.7% per year.

Accelerating Growth: Unable to compare APEN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: APEN is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (0.6%).


Return on Equity

High ROE: APEN has a negative Return on Equity (-252.44%), as it is currently unprofitable.


Next Steps

Financial Health

How is Apollo Endosurgery's financial position?


Financial Position Analysis

Short Term Liabilities: APEN's short term assets ($58.4M) exceed its short term liabilities ($19.0M).

Long Term Liabilities: APEN's short term assets ($58.4M) exceed its long term liabilities ($51.2M).


Debt to Equity History and Analysis

Debt Level: APEN's debt to equity ratio (548.7%) is considered high.

Reducing Debt: APEN's debt to equity ratio has increased from 362.8% to 548.7% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: APEN has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: APEN has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of 14.1% each year.


Next Steps

Dividend

What is Apollo Endosurgery current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate APEN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate APEN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if APEN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if APEN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of APEN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.1yrs

Average management tenure


CEO

Todd Newton (57 yo)

6.33yrs

Tenure

US$647,096

Compensation

Mr. Todd Newton has been the Chief Executive Officer of Apollo Endosurgery, Inc. since July 1, 2014. Mr. Newton served as the Chief Operating Officer and Chief Financial Officer of ArthroCare Corporation f...


CEO Compensation Analysis

Compensation vs Market: Todd's total compensation ($USD647.10K) is about average for companies of similar size in the US market ($USD562.26K).

Compensation vs Earnings: Todd's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Todd Newton
CEO & Director6.33yrsUS$647.10k1.14%
$ 826.0k
Stefanie Cavanaugh
CFO, Treasurer & Secretary5.67yrsUS$463.42k0.083%
$ 60.1k
Bret Schwartzhoff
Vice President5.92yrsUS$476.56k0.10%
$ 72.3k
Sergey Kantsevoy
Co-Founder and Innovation Partnerno datano datano data
Anthony Kalloo
Co-Founder and Innovation Partnerno datano datano data
Robert Hawes
Co-Founder and Innovation Partnerno datano datano data
Peter Cotton
Co-Founder and Innovation Partner15.83yrsno datano data
Christopher Gostout
Co-Founder & Chief Medical Officerno dataUS$1.16m0.075%
$ 54.1k
Sydney Chung
Co-Founder and Innovation Partnerno datano datano data
Pankaj Pasricha
Co-Founder15.83yrsno datano data
John Molesphini
Executive Vice President of Operations2.58yrsno data0.019%
$ 14.0k
John Gillings
Investor Relations Managerno datano datano data

6.1yrs

Average Tenure

57yo

Average Age

Experienced Management: APEN's management team is seasoned and experienced (6.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Todd Newton
CEO & Director6.33yrsUS$647.10k1.14%
$ 826.0k
John Barr
Independent Chairman of the Board1.42yrsUS$94.67k0.021%
$ 15.2k
Julie Shimer
Independent Director2.5yrsUS$94.25k0.030%
$ 21.8k
Rick Anderson
Independent Director7.08yrsno data0.37%
$ 268.0k
William McClellan
Independent Director6.5yrsUS$99.25k0.050%
$ 36.2k
Adrian Park
Member of Scientific Advisory Boardno datano datano data
Mark Talamini
Member of Scientific Advisory Boardno datano datano data
Santiago Horgan
Member of Scientific Advisory Boardno datano datano data
Bruce Robertson
Independent Director12.75yrsno datano data
Jay Redan
Member of Scientific Advisory Boardno datano datano data
Steve McCarus
Member of Scientific Advisory Boardno datano datano data
Jeffrey Marks
Member of Scientific Advisory Boardno datano datano data

6.4yrs

Average Tenure

59.5yo

Average Age

Experienced Board: APEN's board of directors are considered experienced (6.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 23.1%.


Top Shareholders

Company Information

Apollo Endosurgery, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Apollo Endosurgery, Inc.
  • Ticker: APEN
  • Exchange: NasdaqGM
  • Founded: 2005
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$72.452m
  • Shares outstanding: 25.78m
  • Website: https://www.apolloendo.com

Number of Employees


Location

  • Apollo Endosurgery, Inc.
  • Building 1
  • Suite 300
  • Austin
  • Texas
  • 78746
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
APENNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDDec 2016
HQ8FDB (Deutsche Boerse AG)YesCommon StockDEEURDec 2016

Biography

Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices. The company offers OverStitch and OverStitch Sx Endoscopic Suturing Sys...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/24 23:32
End of Day Share Price2020/11/24 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.